Cargando…

The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial

BACKGROUND: Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased do...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiterer, Christian, Hu, Karin, Sljivic, Samir, Falkner von Sonnenburg, Markus, Fleischmann, Edith, Kabon, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821012/
https://www.ncbi.nlm.nih.gov/pubmed/32966587
http://dx.doi.org/10.1111/aas.13713
_version_ 1783639333466537984
author Reiterer, Christian
Hu, Karin
Sljivic, Samir
Falkner von Sonnenburg, Markus
Fleischmann, Edith
Kabon, Barbara
author_facet Reiterer, Christian
Hu, Karin
Sljivic, Samir
Falkner von Sonnenburg, Markus
Fleischmann, Edith
Kabon, Barbara
author_sort Reiterer, Christian
collection PubMed
description BACKGROUND: Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased donor renal transplantation. METHODS: We randomly assigned 34 patients undergoing deceased donor renal transplantation to receive a solution of mannitol or placebo shortly before graft reperfusion until the end of surgery. We evaluated oxidative stress by measuring the static oxidative‐reduction potential (sORP) and the capacity of the oxidative‐reduction potential (cORP). sORP and cORP were measured pre‐operatively, before and within 10 minutes after graft reperfusion, and post‐operatively. RESULTS: Seventeen patients were enrolled in the mannitol group and 17 patients were enrolled in the placebo group. Mannitol had no significant effect on sORP (148.5 mV [136.2; 160.2]) as compared to placebo (143.6 mV [135.8; 163.2], P = .99). There was also no significant difference in cORP between the mannitol (0.22 µC [0.16; 0.36]) and the placebo group (0.22 µC [0.17; 0.38], P = .76). CONCLUSION: Mannitol showed no systemic redox scavenging effects during deceased donor renal transplantation. To evaluate the direct effect of mannitol on the renal graft further studies are needed. Trial registration: ClinicalTrials.gov NCT02705573.
format Online
Article
Text
id pubmed-7821012
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78210122021-01-26 The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial Reiterer, Christian Hu, Karin Sljivic, Samir Falkner von Sonnenburg, Markus Fleischmann, Edith Kabon, Barbara Acta Anaesthesiol Scand General Anaesthesia BACKGROUND: Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased donor renal transplantation. METHODS: We randomly assigned 34 patients undergoing deceased donor renal transplantation to receive a solution of mannitol or placebo shortly before graft reperfusion until the end of surgery. We evaluated oxidative stress by measuring the static oxidative‐reduction potential (sORP) and the capacity of the oxidative‐reduction potential (cORP). sORP and cORP were measured pre‐operatively, before and within 10 minutes after graft reperfusion, and post‐operatively. RESULTS: Seventeen patients were enrolled in the mannitol group and 17 patients were enrolled in the placebo group. Mannitol had no significant effect on sORP (148.5 mV [136.2; 160.2]) as compared to placebo (143.6 mV [135.8; 163.2], P = .99). There was also no significant difference in cORP between the mannitol (0.22 µC [0.16; 0.36]) and the placebo group (0.22 µC [0.17; 0.38], P = .76). CONCLUSION: Mannitol showed no systemic redox scavenging effects during deceased donor renal transplantation. To evaluate the direct effect of mannitol on the renal graft further studies are needed. Trial registration: ClinicalTrials.gov NCT02705573. John Wiley and Sons Inc. 2020-10-15 2021-02 /pmc/articles/PMC7821012/ /pubmed/32966587 http://dx.doi.org/10.1111/aas.13713 Text en © 2020 Medical University of Vienna. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle General Anaesthesia
Reiterer, Christian
Hu, Karin
Sljivic, Samir
Falkner von Sonnenburg, Markus
Fleischmann, Edith
Kabon, Barbara
The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
title The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
title_full The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
title_fullStr The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
title_full_unstemmed The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
title_short The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
title_sort effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—a randomized controlled trial
topic General Anaesthesia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821012/
https://www.ncbi.nlm.nih.gov/pubmed/32966587
http://dx.doi.org/10.1111/aas.13713
work_keys_str_mv AT reitererchristian theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT hukarin theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT sljivicsamir theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT falknervonsonnenburgmarkus theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT fleischmannedith theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT kabonbarbara theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT reitererchristian effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT hukarin effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT sljivicsamir effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT falknervonsonnenburgmarkus effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT fleischmannedith effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial
AT kabonbarbara effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial